These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 12207631

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Enantioselective renal excretion of albendazole metabolites in patients with neurocysticercosis.
    Lanchote VL, Takayanagui OM, Mateus FH.
    Chirality; 2004 Oct; 16(8):520-5. PubMed ID: 15290687
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic optimisation of the treatment of neurocysticercosis.
    Sotelo J, Jung H.
    Clin Pharmacokinet; 1998 Jun; 34(6):503-15. PubMed ID: 9646011
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Plasma disposition and faecal excretion of netobimin metabolites and enantiospecific disposition of albendazole sulphoxide produced in ewes.
    Gokbulut C, Cirak VY, Senlik B.
    Vet Res Commun; 2006 Oct; 30(7):791-805. PubMed ID: 17004041
    [Abstract] [Full Text] [Related]

  • 14. Population pharmacokinetics of albendazole in patients with neurocysticercosis.
    Castro N, Márquez-Caraveo C, Brundage RC, González-Esquivel D, Suárez AM, Góngora F, Jara A, Urizar J, Lanao JM, Jung H.
    Int J Clin Pharmacol Ther; 2009 Nov; 47(11):679-85. PubMed ID: 19840532
    [Abstract] [Full Text] [Related]

  • 15. Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity.
    Lima RM, Ferreira MA, de Jesus Ponte Carvalho TM, Dumêt Fernandes BJ, Takayanagui OM, Garcia HH, Coelho EB, Lanchote VL.
    Br J Clin Pharmacol; 2011 Apr; 71(4):528-35. PubMed ID: 21395645
    [Abstract] [Full Text] [Related]

  • 16. Do albendazole-loaded lipid nanocapsules enhance the bioavailability of albendazole in the brain of healthy mice?
    Fabbri J, Espinosa JP, Pensel PE, Medici SK, Gamboa GU, Benoit JP, Elissondo MC.
    Acta Trop; 2020 Jan; 201():105215. PubMed ID: 31600525
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis.
    Garcia HH, Lescano AG, Lanchote VL, Pretell EJ, Gonzales I, Bustos JA, Takayanagui OM, Bonato PS, Horton J, Saavedra H, Gonzalez AE, Gilman RH, Cysticercosis Working Group in Peru.
    Br J Clin Pharmacol; 2011 Jul; 72(1):77-84. PubMed ID: 21332573
    [Abstract] [Full Text] [Related]

  • 19. Disposition kinetics of albendazole and metabolites in laying hens.
    Bistoletti M, Alvarez L, Lanusse C, Moreno L.
    J Vet Pharmacol Ther; 2013 Apr; 36(2):161-8. PubMed ID: 22533477
    [Abstract] [Full Text] [Related]

  • 20. Dose-dependent systemic exposure of albendazole metabolites in lambs.
    Alvarez L, Suárez G, Ceballos L, Moreno L, Lanusse C.
    J Vet Pharmacol Ther; 2012 Aug; 35(4):365-72. PubMed ID: 21819410
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.